Lexaria Bioscience (LEXX) Gross Profit (2017 - 2026)

Lexaria Bioscience has disclosed Gross Profit across 10 years of filings, most recently posting $20000.0 for Q1 2026.

• Gross Profit for Q1 2026 came in at $20000.0, down 88.51% year-over-year; the trailing twelve-month figure through Feb 2026 was $368000.0 (down 29.66% YoY), and the FY2025 annual result was $703203.0, up 53.05% from the prior year.
• Gross Profit came in at $20000.0 for Q1 2026 at Lexaria Bioscience, down from $174000.0 in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $181203.0 in Q4 2024 to a low of $20000.0 in Q1 2026.
• The 5-year median for Gross Profit is $84000.0 (2024), against an average of $103125.1.
• Across the five-year window, Gross Profit surged 886.04% in 2022 and plunged 88.51% in 2026, its largest moves.
• Lexaria Bioscience's Gross Profit stood at $81940.0 in 2022, then surged by 78.74% to $146456.0 in 2023, then rose by 23.73% to $181203.0 in 2024, then declined by 3.98% to $174000.0 in 2025, then slumped by 88.51% to $20000.0 in 2026.
• The last three Gross Profit figures came in at $20000.0 (Q1 2026), $174000.0 (Q3 2025), and $174000.0 (Q2 2025), per Business Quant data.